Terms ending in 2038
Every in-force patent on Epicentrx, Inc.'s record whose computed term ends in 2038, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 12,291,726 | A549 Host Cells Comprising a Recombinant Oncolytic Adenovirus with Modified E1A Cancer-Specific Promoter In force · High confidence | Epicentrx, Inc. | In force | High confidence | |
| US 11,576,895 | Compositions and Methods for Intravenous Administration of 2-Bromo-1-(3,3-Dinitroazetidin-1-YL)ETHANONE In force · High confidence | Epicentrx, Inc. | In force | High confidence | |
| US 11,834,492 | Human IL-10 Receptor Alpha Fusion Proteins In force · High confidence | Epicentrx, Inc. | In force | High confidence | |
| US 11,744,859 | Compositions and Methods for Parenteral Administration of Therapeutic Agents In force · High confidence | Epicentrx, Inc. | In force | High confidence |
4 of 4 patents shown. Soonest term end first, then patent number.
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.